Drug Profile
Research programme: melanin-concentrating hormone receptor 1 antagonists - Neurocrine Biosciences
Latest Information Update: 24 Feb 2011
Price :
$50
*
At a glance
- Originator Neurocrine Biosciences
- Class
- Mechanism of Action MCHR1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder; Obesity
Most Recent Events
- 10 Jul 2006 No development reported - Preclinical for Anxiety disorders in USA (unspecified route)
- 10 Jul 2006 No development reported - Preclinical for Depression in USA (unspecified route)
- 10 Jul 2006 No development reported - Preclinical for Obesity in USA (unspecified route)